TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07148128: Phase 1/2a Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of WEF-001 as Monotherapy in Advanced KRAS-Mutant Solid Tumours.

Sponsor: Auricula Biosciences Inc. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 110 pts

Competing Trials Overlap

5 Active Trials

Excess Burn Exposure

$12,566,400

Rescue Site Savings

+$8,285,970

Unlock Full NCT07148128 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07148128 Rescue Dossier →